ArticlePLoS neglected tropical diseases2016
Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A need to raise the bar - A systematic review of temporal trends in diagnostics for Japanese encephalitis virus infection, and perspectives for future research.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Pooled it
- Pooled it
- Detection of Japanese encephalitis virus inParasite epidemiology and control · 2026Article
- Evaluation of protective efficacy of an inactivated Japanese encephalitis virus genotype Ⅴ strain in mice.NPJ vaccines · 2026Article
- Virtual screening, molecular dynamics simulations, and antiviral evaluation of Ocimum basilicum phytoconstituents against Japanese encephalitis virus.Archives of virology · 2026Article
- The Emerging JEV Genotype 5 Exhibits Distinct Codon Usage Characteristics.Pathogens (Basel, Switzerland) · 2026Article
- Isolation and Transcriptomic Characterization of Genotype 5 Japanese Encephalitis Virus E138K Mutant Strain.Transboundary and emerging diseases · 2026Article
- Isolation and characterization of Japanese encephalitis virus genotype I from pig provides evidence for the presence of the virus in nasal secretion and co-circulation of JEV genotypes in Assam, India.Frontiers in cellular and infection microbiology · 2026Article
- Non-Dominant Genotypes (GII, GIV and GV) of Japanese Encephalitis Virus Exhibit an Elevated Evolutionary Rate in Nature.Microorganisms · 2025Article
- Thioester-Containing Protein TEP27 inInternational journal of molecular sciences · 2025Article
- Advances and Challenges in Vaccination and Therapeutic Strategies Against Japanese Encephalitis Virus.Pathogens (Basel, Switzerland) · 2025Review
- The hidden threats posed by Japanese encephalitis virus genotype V.Journal of virology · 2025Review
- Rutin Attenuates Virus Entry and Replication and Exerts Neuroprotection in Experimental Models of Japanese Encephalitis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Japanese Encephalitis Virus Genotype 5 Infectious Clone and Reporter System for Antiviral Evaluation.Journal of medical virology · 2025Article
- Sheep serve as amplifying hosts of Japanese encephalitis virus, increasing the risk of human infection.Science advances · 2025Article
- The alarming spread of Japanese encephalitis: A growing public health concern.Open veterinary journal · 2025Review
- Partial protective efficacy of the current licensed Japanese encephalitis live vaccine against the emerging genotype I Japanese encephalitis virus isolated from sheep.Frontiers in immunology · 2025Article
- Distribution and frequency of genetic mutations in three insecticide targets in field populations ofFrontiers in cellular and infection microbiology · 2025Article
- Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus.Emerging microbes & infections · 2024Article
- Characterization of genotype V Japanese encephalitis virus isolates from Republic of Korea.Emerging microbes & infections · 2024Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current Japanese encephalitis (JE) vaccine derived from G3 JE virus (JEV) can induce protective immunity against G1-G4 JEV genotypes. However, protective efficacy against the emerging G5 genotype has not been reported. METHODS/PRINCIPAL
findingsUsing in vitro and in vivo tests, biological phenotype and cross-immunoreactions were compared between G3 JEV and G5 JEV (wild strains). The PRNT90 method was used to detect neutralizing antibodies against different genotypes of JEV in JE vaccine-immunized subjects and JE patients. In JE vaccine-immunized mice, the lethal challenge protection rates against G3 and G5 JEV wild strains were 100% and 50%, respectively. The seroconversion rates (SCRs) of virus antibodies against G3 and G5 JEV among vaccinated healthy subjects were 100% and 35%, respectively. All clinically identified JE patients showed high levels of G3 JEV neutralizing antibodies (≥1:10-1280) with positive serum geometric mean titers (GMTs) of 43.2, while for G5 JEV, neutralizing antibody conversion rates were only 64% with positive serum GMTs of 11.14. Moreover, the positive rate of JEV neutralizing antibodies against G5 JEV in pediatric patients was lower than in adults. CONCLUSIONS/SIGNIFICANCE: Low levels of neutralizing/protective antibodies induced by the current JE vaccine, based on the G3 genotype, were observed against the emerging G5 JEV genotype. Our results demonstrate the need for more detailed studies to reevaluate whether or not the apparent emergence of G5 JEV can be attributed to failure of the current vaccine to induce appropriate immune protectivity against this genotype of JEV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.